Bladder cancer: A simple model becomes complex

Current Genomics

Volumn 13, Issue 5, 2012, Pages 395-415

  Di Pierro, Giovanni Battista ^a   Gulia, Caterina ^a   Cristini, Cristiano ^a   Fraietta, Giorgio ^b   Grande, Pietro ^a   Marini, Lorenzo ^a   Gentile, Vincenzo ^a   Piergentili, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bladder carcinoma; Carcinoma in situ; CIS; Environmental causes of bladder carcinoma; Epigenetics; FGFR3; MICB; NMIBC; Small noncoding RNA; TP53; Urinary tract

Indexed keywords

ACROLEIN; ALPHA TOCOPHEROL; ARSENIC; BONE MORPHOGENETIC PROTEIN 9; COPPER; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; CYCLOPHOSPHAMIDE; EOMESODERMIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE; INHIBITOR OF DIFFERENTIATION 1; KERATIN; MICRORNA; POLO LIKE KINASE 1; PROTEIN P53; PROTEIN P63; RETINOBLASTOMA BINDING PROTEIN; RETINOIC ACID RECEPTOR BETA; SELENIUM; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX3; UNINDEXED DRUG; ZINC;

5' UNTRANSLATED REGION; ADRENAL METASTASIS; ANGIOGENESIS; APOPTOSIS; BLADDER CANCER; BONE METASTASIS; BRACHYTHERAPY; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVATION; CELL ADHESION; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMORBIDITY; CYSTECTOMY; DETOXIFICATION; DIETARY INTAKE; DNA METHYLATION; DNA REPLICATION; DOWN REGULATION; DRINKING BEHAVIOR; ENVIRONMENTAL FACTOR; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; G1 PHASE CELL CYCLE CHECKPOINT; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; HEART METASTASIS; HISTONE MODIFICATION; HUMAN; KIDNEY METASTASIS; LAMINA PROPRIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MENINGEAL METASTASIS; NONHUMAN; NUCLEOTIDE METABOLISM; PANCREAS METASTASIS; PATIENT CARE; PROSTATECTOMY; REVIEW; SIGNAL TRANSDUCTION; SMOKING; SOCIAL STATUS; SPLEEN METASTASIS; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR LOCALIZATION; TUMOR VOLUME; UPREGULATION; VISCERAL METASTASIS;

EID: 84863959507     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920212801619232     Document Type: Review

References (268)

1. Babjuk, M.; Oosterlinck, W.; Sylvester R.; Kaasinen, E.; Böhle, A.; Palou-Redorta, J.; European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol., 2008, 54, 303-314.
2. Zhang, S.W.; Ma, J.H.; Li, M.; Na, Y.-Q.; Chen, W.-Q. Incidence trends of bladder cancer in cities and counties in China. Chin. J. Urol., 2009, 30, 673-676.
3. Hisataki, T.; Miyao, N.; Masumori, N.; Takahashi, A.; Sasai, M.; Yanase, M.; Itoh, N.; Tsukamoto, T. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology, 2000, 55, 663-667.
4. Pelucchi, C.; Bosetti, C.; Negri, E.; Malvezzi, M.; La Vecchia, C. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol., 2006, 3, 327-340.
5. Murta-Nascimento, C.; Schmitz-Drager, B.J.; Zeegers, M.P.; Steineck, G.; Kogevinas, M.; Real, F.X.; Malats, N. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J. Urol., 2007, 25, 285-295.
6. Freedman, N.D.; Silverman, D.T.; Hollenbeck, A.R.; Schatzkin, A.; Abnet, C.C. Association between smoking and risk of bladder cancer among men and women. JAMA, 2011, 306, 737-745.
7. Yang, M. A current global view of environmental and occupational cancers. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev., 2011, 29, 223-249.
8. Dietrich, H.G.; Golka, K. Bladder tumors and aromatic amines-Historical milestones from Ludwig Rehn to Wilhelm Hueper. Front. Biosci. (Elite Ed), 2012, 4, 279-288.
9. Yang, C.Y.; Chiu, H.F.; Chang, C.C.; Ho, S.C.; Wu, T.N. Bladder cancer mortality reduction after installation of a tap-water supply system in an arseniousendemic area in southwestern Taiwan. Environ. Res., 2005, 98, 127-132.
10. Tsuda, T.; Babazono, A.; Yamamoto, E.; Kurumatani, N.; Mino, Y.; Ogawa, T.; Kishi, Y.; Aoyama, K. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. Am. J. Epidemiol., 1995, 141, 198-209.
11. Hopenhayn-Rich, C.; Biggs, M.L.; Fuchs, A. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology, 1996, 7, 117-124.
12. Fernández, M.I.; López, J.F.; Vivaldi, B.; Coz, F. Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure. J. Urol., 2012, 187, 856-861.
13. Lesseura, C.; Gilbert-Diamonda, D.; Andrewa, A.S.; Ekstroma, R.M.; Li, Z.; Kelseyd, K.T.; Marsita, C.J.; Karagasa, M.R. A casecontrol study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire. Toxicol. Lett., 2012, 210, 100-106.
14. Mazdak, H.; Yazdekhasti, F.; Movahedian, A.; Mirkheshti, N.; Shafieian, M. The comparative study of serum iron, copper, and zinc levels between bladder cancer patients and a control group. Int. Urol. Nephrol., 2010, 42, 89-93.
15. Reszka, E. Selenoproteins in bladder cancer. Clin. Chim. Acta, 2012, 413, 847-854.
16. Mazdak, H.; Zia, H. Vitamin E reduces superficial bladder cancer recurrence: a randomized controlled trial. Int. J. Prev. Med., 2012, 3, 110-115.
17. Pelucchi, C.; Galeone, C.; Tramacere, I.; Bagnardi, V.; Negri, E.; Islami, F.; Scotti, L.; Bellocco, R.; Corrao, G.; Boffetta, P.; La Vecchia, C. Alcohol drinking and bladder cancer risk: a metaanalysis. Ann. Oncol., 2011, DOI: 10.1093/annonc/mdr460.
18. World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR). Cancers. In: Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR 2007; 244-321.
19. Boffetta, P.; Hashibe, M. Alcohol and cancer. Lancet Oncol., 2006, 7, 149-156.
20. Secretan, B.; Straif, K.; Baan, R.; Grosse, Y.; El Ghissassi, F.; Bouvard, V.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; Cogliano, V.; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol., 2009, 10, 1033-1034.
21. International Agency for Research on Cancer (IARC). Alcohol Consumption and Ethyl Carbamate. Lyon, France: IARC 2010.
22. Tramacere, I.; Scotti, L.; Jenab, M.; Bagnardi, V.; Bellocco, R.; Rota, M.; Corrao, G.; Bravi, F.; Boffetta, P.; La Vecchia, C. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int. J. Cancer, 2010, 126, 1474-1486.
23. Tsukamoto, S.; Kanegae, T.; Uchigasaki, S.; Kitazawa, M.; Fujioka, T.; Fujioka, S.; Imamura, Y.; Nagoya, T.; Shimamura, M.; Mieda, Y. Changes in free and bound alcohol metabolites in the urine during ethanol oxidation. Arukoru Kenkyuto Yakubutsu Ison., 1993, 28, 441-452.
24. Boffetta, P.; Hashibe, M.; La Vecchia, C.; Zatonski, W.; Rehm, J. The burden of cancer attributable to alcohol drinking. Int. J. Cancer., 2006, 119, 884-887.
25. Mao, Q.; Lin, Y.; Zheng, X.; Qin, J.; Yang, K.; Xie, L. A metaanalysis of alcohol intake and risk of bladder cancer. Cancer Causes Control, 2010, 21, 1843-1850.
26. Mao, Q.-Q.; Dai, Y.; Lin, Y.-W.; Qin, J.; Xie, L.-P.; Zheng, X.-Y. Milk consumption and bladder cancer risk: a meta-analysis of published epidemiological studies. Nutr. Cancer, 2011, 63, 1263-1271.
27. Larsson, S.C.; Orsini, N.; Wolk, A. Milk, milk products and lactose intake and ovarian cancer risk: a meta-analysis of epidemiological studies. Int. J. Cancer, 2006, 118, 431-441.
28. Qin, L.Q.; Xu, J.Y.; Wang, P.Y.; Tong, J.; Hoshi, K. Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. Asia Pac. J. Clin. Nutr., 2007, 16, 467-476.
29. Li, F.; An, S.L.; Zhou, Y.; Liang, Z.K.; Jiao, Z.J.; Jing, Y.M.; Wan, P.; Shi, X.J.; Tan, W.L. Milk and dairy consumption and risk of bladder cancer: a meta-analysis. Urology, 2011, 78, 1298-1305.
30. Lampe, J.W. Dairy products and cancer. J. Am. Coll. Nutr., 2011, 30(5 Suppl 1), 464S-470S.
31. Mostafa, M.H.; Sheweita, S.A.; O'Connor, P.J. Relationship between Schistosomiasis and bladder cancer. Clin. Microbiol. Rev., 1999, 12, 97-111.
32. Shen, Y.; Liu, Y.; Liu, S.; Zhang, A. The association between-330T/G polymorphism of interleukin 2 gene and bladder cancer. DNA Cell Biol., 2012, DOI: 10.1089/dna.2011.1476.
33. Chu, H.; Ma, L.; Wang, M.; Shi, D.; Qin, C.; Yuan, L.; Yin, C.; Zhang, Z. The polymorphisms of IL-4, IL-4R and IL-13 genes and bladder cancer risk in a Chinese population: a case-control study. Mol. Biol. Rep., 2012, 39, 5349-5357.
34. Mathé, E.; Nguyen, G.H.; Funamizu, N.; He, P.; Moake, M.; Croce, C.M.; Hussain, S.P. Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide. Int. J. Cancer, 2011, DOI: 10.1002/ijc.26403.
35. Nieder, A.M.; Porter, M.P.; Soloway, M.S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J. Urol., 2008, 180, 2005-2009.
36. Nielsen, M.E.; Shariat, S.F.; Karakiewicz, P.I.; Lotan, Y.; Rogers, C.G.; Amiel, G.E.; Bastian, P.J.; Vazina, A.; Gupta, A.; Lerner, S.P.; Sagalowsky, A.I.; Schoenberg, M.P.; Palapattu, G.S.; Bladder Cancer Research Consortium (BCRC). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur. Urol., 2007, 51, 699-706.
37. Kaldor, J.M.; Day, N.E.; Kittelmann, B.; Pettersson, F.; Langmark, F.; Pedersen, D.; Prior, P.; Neal, F.; Karjalainen, S.; Bell, J.; Choi, W.; Koch, M.; Band, P.; Pompe-Kirn, V.; Garton, C.; Staneczek, W.; Zarén, B.; Stovall, M.; Boffetta, P. Bladder tumors following chemotherapy and radiotherapy for ovarian cancer: a case control study. Int. J. Cancer, 1995, 63, 1-6.
38. Travis, L.B.; Curtis, R.E.; Glimelius, B.; Holowaty, E.J.; Van Leeuwen, F.E.; Lynch, C.F.; Hagenbeek, A.; Stovall, M.; Banks, P.M.; Adami, J.; Gospodarowicz, M.K.; Wacholder, S.; Inskip, P.D.; Tucker, M.A.; Boice, J.D. Jr. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J. Natl. Cancer Inst., 1995, 87, 524-531.
39. Fajkovic, H.; Halpern, J.A.; Cha, E.K.; Bahadori, A.; Chromecki, T.F.; Karakiewicz, P.I.; Breinl, E.; Merseburger, A.S.; Shariat, S.F. Impact of gender on bladder cancer incidence, staging, and prognosis. World J. Urol., 2011, 29, 457-463.
40. Tilki, D.; Svatek, R.S.; Karakiewicz, P.I.; Isbarn, H.; Reich, O.; Kassouf, W.; Fradet, Y.; Novara, G.; Fritsche, H.M.; Bastian, P.J.; Izawa, J.I.; Stief, C.G.; Ficarra, V.; Lerner, S.P.; Schoenberg, M.; Dinney, C.P.; Skinner, E.; Lotan, Y.; Sagalowsky, A.I.; Shariat, S.F. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J. Urol., 2010, 183, 87-93.
41. Liberman, D.; Alasker, A.; Sun, M.; Ismail, S.; Lughezzani, G.; Jeldres, C.; Budaus, L.; Thuret, R.; Shariat, S.F.; Widmer, H.; Perrotte, P.; Graefen, M.; Montorsi, F.; Karakiewicz, P.I. Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study. BJU Int., 2011, 107, 905-911.
42. May, M.; Bastian, P.J.; Brookman-May, S.; Fritsche, H.M.; Tilki, D.; Otto, W.; Bolenz, C.; Gilfrich, C.; Trojan, L.; Herrmann, E.; Moritz, R.; Tiemann, A.; Müller, S.C.; Ellinger, J.; Buchner, A.; Stief, C.G.; Wieland, W.F.; Höfner, T.; Hohenfellner, M.; Haferkamp, A.; Roigas, J.; Zacharias, M.; Nuhn, P.; Burger, M. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urol. Oncol., 2011, DOI: 10.1016/j.urolonc.2011.09.011.
43. Micheli, A.; Mariotto, A.; Giorgi Rossi, A.; Gatta, G.; Muti, P. The prognostic role of gender in survival of adult cancer patients. Eur. J. Cancer, 1998, 34, 2271-2278.
44. Shariat, S.F.; Sfakianos, J.P.; Droller, M.J.; Karakiewicz, P.I.; Meryn, S.; Bochner, B.H. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int., 2010, 105, 300-308.
45. Scosyrev, E.; Trivedi, D.; Messing, E. Female bladder cancer: incidence, treatment, and outcome. Curr. Opin. Urol., 2010, 20, 404-408.
46. rd, W. Racial disparity in bladder cancer: trends in tumor presentation at diagnosis. J. Urol., 2006, 176, 927-934.
47. Yee, D.S.; Ishill, N.M.; Lowrance, W.T.; Herr, H.W.; Elkin, E.B. Ethnic differences in bladder cancer survival. Urology, 2011, 78, 544-549.
48. rd, W.; Dunn, R.L.; Williams, C.; Lee, C.T. Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. J. Am. Coll. Surg., 2006, 202, 284-290.
49. Gore, J.L.; Kwan, L.; Saigal, C.S.; Litwin, M.S. Marriage and mortality in bladder carcinoma. Cancer, 2005, 104, 1188-1194.
50. Babjuk, M.; Oosterlinck, W.; Sylvester, R.; Kaasinen, E.; Böhle, A.; Palou-Redorta, J.; Rouprêt, M. EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol., 2012, 59, 997-1008.
51. Stenzl, A.; Cowan, N.C.; De Santis, M.; Kuczyk, M.A.; Merseburger, A.S.; Ribal, M.J.; Sherif, A.; Witjes, J.A. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur. Urol., 2012, 59, 1009-1018.
52. Sylvester, R.J.; van der Meijden, A.P.; Oosterlinck, W.; Witjes, J.A.; Bouffioux, C.; Denis, L.; Newling, D.W.; Kurth, K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol., 2006, 49, 466-475.
53. Kaufman, D.S.; Shipley, W.U.; Feldman, A.S. Bladder cancer. Lancet, 2009, 374, 239-249.
54. Babaian, R.J.; Johnson, D.E.; Llamas, L.; Ayala, A.G. Metastases from transitional cell carcinoma of urinary bladder. Urology, 1980, 16, 142-144.
55. Hermann, G.G.; Horn, T.; Steven, K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J. Urol., 1998, 159, 91-94.
56. Bane, B.L.; Rao, J.Y. Pathology and staging of bladder cancer. Semin. Oncol., 1996, 23, 549-570.
57. Fernandez-Gomez, J.; Solsona, E.; Unda, M.; Martinez-Piñeiro, L.; Gonzalez, M.; Hernandez, R.; Madero, R.; Ojea, A.; Pertusa, C.; Rodriguez-Molina, J.; Camacho, J.E.; Isorna, S.; Rabadan, M.; Astobieta, A.; Montesinos, M.; Muntañola, P.; Gimeno, A.; Blas, M.; Martinez-Piñeiro, J.A.; Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur. Urol., 2008, 53, 992-1001.
58. van Rhijn, B.W.; Burger, M.; Lotan, Y.; Solsona, E.; Stief, C.G.; Sylvester, R.J.; Witjes, J.A.; Zlotta, A.R. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol., 2009, 56, 430-442.
59. Youssef, R.F., Lotan, Y. Predictors of outcome of non-muscleinvasive and muscle-invasive bladder cancer. TheScientificWorld-JOURNAL, 2011, 11, 369-381.
60. Stein, J.P.; Skinner, D.G. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J. Urol., 2006, 24, 296-304.
61. Sternberg, C.N.; Donat, S.M.; Bellmunt, J.; Millikan, R.E.; Stadler, W.; De Mulder, P.; Sherif, A.; von der Maase, H.; Tsukamoto, T.; Soloway, M.S. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology, 2007, 69(1 Suppl), 62-79.
62. Calabro, F.; Sternberg, C.N. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur. Urol., 2009, 55, 348-358.
63. Clark, P.E. Neoadjuvant versus adjuvant chemotherapy for muscleinvasive bladder cancer. Expert Rev. Anticancer Ther., 2009, 9, 821-830.
64. Miyake, H.; Hara, I.; Kamidono, S.; Eto, H. Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J. Urol., 2004, 172, 1127-1129.
65. Jones, T.D.; Eble, J.N.; Wang, M.; MacLennan, G.T.; Delahunt, B.; Brunelli, M.; Martignoni, G.; Lopez-Beltran, A.; Bonsib, S.M.; Ulbright, T.M.; Zhang, S.; Nigro, K.; Cheng, L. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin. Cancer Res., 2005; 11, 7226-7223.
66. Catto, J.W.; Hartmann, A.; Stoehr, R.; Bolderson, E.; Rehman, I.; Rosario, D.J.; Hamdy, F.C.; Meuth, M. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J. Urol., 2006, 175, 2323-2330.
67. Catto, J.W.; Yates, D.R.; Rehman, I.; Azzouzi, A.R.; Patterson, J.; Sibony, M.; Cussenot, O.; Hamdy, F.C. Behavior of urothelial carcinoma with respect to anatomical location. J. Urol., 2007, 177, 1715-1720.
68. Gaisa, N.T.; Graham, T.A.; McDonald, S.A.C.; Cañadillas-Lopez, S.; Poulsom, R.; Heidenreich, A.; Jakse, G.; Tadrous, P.J.; Knuechel, R., Wright, N.A. The human urothelium consists of multiple clonal units, each maintained by a stem cell. J. Pathol., 2011, 225, 163-171.
69. Bakkar, A.A.; Wallerand, H.; Radvanyi, F.; Lahaye, J.B.; Pissard, S.; Lecerf, L.; Kouyoumdjian, J.C.; Abbou, C.C.; Pairon, J.C.; Jaurand, M.C.; Thiery, J.P.; Chopin, D.K.; de Medina, S.G. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res., 2003, 63, 8108-8112.
70. van Rhijn, B.W.; van der Kwast, T.H.; Vis, A.N.; Kirkels, W.J.; Boevé, E.R.; Jöbsis, A.C.; Zwarthoff, E.C. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res., 2004, 64, 1911-1914.
71. Hernandez, S.; Lopez-Knowles, E.; Lloreta, J.; Kogevinas, M.; Jaramillo, R.; Amorós, A.; Tardón, A.; García-Closas, R.; Serra, C.; Carrato, A.; Malats, N.; Real, F.X. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin. Cancer Res., 2005, 11, 5444-5450.
72. Lamy, A.; Gobet, F.; Laurent, M.; Blanchard, F.; Varin, C.; Moulin, C.; Andreou, A.; Frebourg, T.; Pfister, C. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J. Urol., 2006, 176, 2686-2689.
73. Malats, N,; Bustos, A.; Nascimento, C.M.; Fernandez, F.; Rivas, M.; Puente, D.; Kogevinas, M.; Real, F.X. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol., 2005, 6, 678-686.
74. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature, 2000, 408, 307-310.
75. Choi, W.; Shah, J.B.; Tran, M.; Svatek, R.; Marquis, L.; Lee, I.-L.; Yu, D.; Adam, L.; Wen, S.; Shen, Y.; Dinney, C.; McConkey, D.J.; Siefker-Radtke, A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One, 2012, 7(1):e30206. doi:10.1371/journal.pone.0030206
76. Shariat, S.F.; Zlotta, A.R.; Ashfaq, R.; Sagalowsky, A.I.; Lotan, Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod. Pathol., 2007, 20, 445-459.
77. Shariat, S.F.; Ashfaq, R.; Sagalowsky, A.I.; Lotan, Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J. Urol., 2007, 177, 481-487.
78. Shariat, S.F.; Lotan, Y.; Karakiewicz, P.I.; Ashfaq, R.; Isbarn, H.; Fradet, Y.; Bastian, P.J.; Nielsen, M.E.; Capitanio, U.; Jeldres, C.; Montorsi, F.; Müller, S.C.; Karam, J.A.; Heukamp, L.C.; Netto, G.; Lerner, S.P., Sagalowsky, A.I.; Cote, R.J. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J. Urol., 2009, 182, 907-913.
79. Shariat, S.F.; Karam, J.A.; Lerner, S.P. Molecular markers in bladder cancer. Curr. Opin. Urol., 2008, 18, 1-8.
80. Bolenz, C.; Lotan, Y. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat. Clin. Pract. Urol., 2008, 5, 676-685.
81. WAF1/Cip1 by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells. Cancer Lett., 2008, 265, 206-214.
82. Sherr, C.J.; Roberts, J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 1999, 13, 1501-1512.
83. Shariat, S.F.; Karakiewicz, P.I.; Ashfaq, R.; Lerner, S.P.; Palapattu, G.S.; Cote, R.J.; Sagalowsky, A.I.; Lotan, Y. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer, 2008, 112, 315-325.
84. Shariat, S.F.; Chade, D.C.; Karakiewicz, P.I.; Ashfaq, R.; Isbarn, H.; Fradet, Y.; Bastian, P.J.; Nielsen, M.E.; Capitanio, U.; Jeldres, C.; Montorsi, F.; Lerner, S.P.; Sagalowsky, A.I.; Cote, R.J.; Lotan, Y. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J. Urol., 2010, 183, 68-75.
85. Shariat, S.F.; Bolenz, C.; Karakiewicz, P.I.; Fradet, Y.; Ashfaq, R.; Bastian, P.J.; Nielsen, M.E.; Capitanio, U.; Jeldres, C.; Rigaud, J.; Müller, S.C.; Lerner, S.P.; Montorsi, F.; Sagalowsky, A.I.; Cote, R.J.; Lotan, Y. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int., 2010, 105, 489-495.
86. Yu, C.; Zhang, Z.; Liao, W.; Zhao, X.; Liu, L.; Wu, Y.; Liu, Z.; Li, Y.; Zhong, Y.; Chen, K.; Li, J.; Zhou, F.; Song, L. The tumorsuppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Carcinogenesis, 2012, 33, 678-686.
87. Stein, J.P.; Ginsberg, D.A.; Grossfeld, G.D.; Chatterjee, S.J.; Esrig, D.; Dickinson, M.G.; Groshen, S.; Taylor, C.R.; Jones, P.A.; Skinner, D.G.; Cote, R.J. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 1998; 90, 1072-1079.
88. Shariat, S.F.; Ashfaq, R.; Sagalowsky, A.I.; Lotan, Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum. Pathol., 2006, 37, 1568-1576.
89. Yurakh, A.O.; Ramos, D.; Calabuig-Fariñas, S.; López-Guerrero, J.A.; Rubio, J.; Solsona, E.; Romanenko, A.M.; Vozianov, A.F.; Pellin, A.; Llombart-Bosch, A. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur. Urol., 2006, 50, 506-515.
90. Zhang, Z.; Zhang, G.; Kong, C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Urol. Oncol., 2011, DOI: 10.1016/j.urolonc.2011.11.028.
91. McKnight, J.J.; Gray, S.B.; O'Kane, H.F.; Johnston, S.R.; Williamson, K.E. Apoptosis and chemotherapy for bladder cancer. J. Urol., 2005, 173, 683-690.
92. Karam, J.A.; Lotan, Y.; Karakiewicz, P.I.; Ashfaq, R.; Sagalowsky, A.I.; Roehrborn, C.G.; Shariat, S.F. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol., 2007, 8, 128-136.
93. Margulis, V.; Lotan, Y.; Montorsi, F.; Shariat, S.F. Predicting survival after radical cystectomy for bladder cancer. BJU Int., 2008, 102, 15-22.
94. Yamana, K.; Bilim, V.; Hara, N.; Kasahara, T.; Itoi, T.; Maruyama, R.; Nishiyama, T.; Takahashi, K.; Tomita, Y. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br. J. Cancer, 2005, 93, 544-551.
95. Svatek, R.S.; Herman, M.P.; Lotan, Y.; Casella, R.; Hsieh, J.T.; Sagalowsky, A.I.; Shariat, S.F. Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer, 2006, 106, 1701-1707.
96. Karam, J.A.; Lotan, Y.; Ashfaq, R.; Sagalowsky, A.I.; Shariat, S.F. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology, 2007, 70, 482-486.
97. Shariat, S.F.; Ashfaq, R.; Karakiewicz, P.I.; Saeedi, O.; Sagalowsky, A.I.; Lotan, Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer, 2007, 109, 1106-1113.
98. Shariat, S.F.; Karakiewicz, P.I.; Godoy, G.; Karam, J.A.; Ashfaq, R.; Fradet, Y.; Isbarn, H.; Montorsi, F.; Jeldres, C.; Bastian, P.J.; Nielsen, M.E.; Müller, S.C.; Sagalowsky, A.I.; Lotan, Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin. Cancer Res., 2009, 15, 7012-7019.
99. Che, X.; Yang, D.; Zong, H.; Wang, J.; Li, X.; Chen, F.; Chen, X.; Song, X. Nuclear cIAP1 overexpression is a tumor stage-and grade-independent predictor of poor prognosis in human bladder cancer patients. Urol. Oncol., 2011, DOI: 10.1016/j.urolonc.2010.12.016.
100. Ewald, F.; Ueffing, N.; Brockmann, L.; Hader, C.; Telieps, T.; Schuster, M.; Schulz, W.A.; Schmitz, I. The role of c-FLIP splice variants in urothelial tumors. Cell Death Dis., 2011, DOI: 10.1038/cddis.2011.131.
101. Li, Y.; Jin, X.; Li, J.; Jin, X.; Yu, J.; Sun, X.; Chu, Y.; Xu, C.; Li, X.; Wang, X.; Kakehi, Y.; Wu, X. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis. Urology, 2012, DOI: 10.1016/j.urology.2011.11.011.
102. Shariat, S.F.; Youssef, R.F.; Gupta, A.; Chade, D.C.; Karakiewicz, P.I.; Isbarn, H.; Jeldres, C.; Sagalowsky, A.I.; Ashfaq, R.; Lotan, Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J. Urol., 2010, 183, 1744-1750.
103. Miyata, Y.; Kanda, S.; Ohba, K.; Nomata, K.; Hayashida, Y.; Eguchi, J.; Hayashi, T.; Kanetake, H. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A,-C, and-D. Clin. Cancer Res., 2006, 12, 800-806.
104. Zu, X.; Tang, Z.; Li, Y.; Gao, N.; Ding, J.; Qi, L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int., 2006, 98, 1090-1093.
105. Chodak, G.W.; Hospelhorn, V.; Judge, S.M.; Mayforth, R.; Koeppen, H.; Sasse, J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res., 1988, 48, 2083-2088.
106. Wu, X.R.; Kong, X.P.; Pellicer, A.; Kreibich, G.; Sun, T.T. Uroplakins in urothelial biology, function, and disease. Kidney Int., 2009, 75, 1153-1165.
107. Huang, H.Y.; Shariat, S.F.; Sun, T.T.; Lepor, H.; Shapiro, E.; Hsieh, J.T.; Ashfaq, R.; Lotan, Y.; Wu, X.R. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum. Pathol., 2007, 38, 1703-1713.
108. Krüger, S.; Weitsch, G.; Büttner, H.; Matthiensen, A.; Böhmer, T.; Marquardt, T.; Sayk, F.; Feller, A.C.; Böhle, A. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int. J. Cancer, 2002, 102, 514-518.
109. Kolla, S.B.; Seth, A.; Singh, M.K.; Gupta, N.P.; Hemal, A.K.; Dogra, P.N.; Kumar, R. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int. Urol. Nephrol., 2008, 40, 321-327.
110. Kassouf, W.; Black, P.C.; Tuziak, T.; Bondaruk, J.; Lee, S.; Brown, G.A.; Adam, L.; Wei, C.; Baggerly, K.; Bar-Eli, M.; McConkey, D.; Czerniak, B.; Dinney, C.P. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J. Urol., 2008, 179, 353-358.
111. Liedberg, F.; Anderson, H.; Chebil, G.; Gudjonsson, S.; Höglund, M.; Lindgren, D.; Lundberg, L.M.; Lövgren, K.; Fernö, M.; Månsson, W. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol. Oncol., 2008, 26, 17-24.
112. Blehm, K.N.; Spiess, P.E.; Bondaruk, J.E.; Dujka, M.E.; Villares, G.J.; Zhao, Y.J.; Bogler, O.; Aldape, K.D.; Grossman, H.B.; Adam, L.; McConkey, D.J.; Czerniak, B.A.; Dinney, C.P.; Bar-Eli, M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin. Cancer Res., 2006, 12, 4671-4677.
113. Villares, G.J.; Zigler, M.; Blehm, K.; Bogdan, C.; McConkey, D.; Colin, D.; Bar-Eli, M. Targeting EGFR in bladder cancer. World J. Urol., 2007, 25, 573-579.
114. Zhang, Z.T.; Pak, J.; Huang, H.Y.; Shapiro, E.; Sun, T.T.; Pellicer, A.; Wu, X.R. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene, 2001, 20, 1973-1980.
115. Shan, G.Y.; Zhang, Z.; Chen, Q.G.; Yu, X.Y.; Liu, G.B.; Kong, C.Z. Overexpression of RIN1 associates with tumor grade and progression in patients of bladder urothelial carcinoma. Tumor Biol., 2012, DOI: 10.1007/s13277-011-0311-1
116. Wu, S.Y.; Lan, S.H.; Cheng, D.E.; Chen, W.K.; Shen, C.H.; Lee, Y.R.; Zuchini, R.; Liu, H.S. Ras-related tumorigenesis is suppressed by BNIP3-mediated autophagy through inhibition of cell proliferation. Neoplasia, 2011, 13, 1171-1182.
117. Jebar, A.H.; Hurst, C.D.; Tomlinson, D.C.; Johnston, C.; Taylor, C.F.; Knowles, M.A. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 2005, 24, 5218-5225.
118. Aveyard, J.S.; Skilleter, A.; Habuchi, T.; Knowles, M.A. Somatic mutation of PTEN in bladder carcinoma. Br. J. Cancer, 1999, 80, 904-908.
119. Lopez-Knowles, E.; Hernandez, S.; Malats, N.; Kogevinas, M.; Lloreta, J.; Carrato, A.; Tardón, A.; Serra, C.; Real, F.X. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res., 2006, 66, 7401-7404.
120. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7, 606-619.
121. Dyrskjot, L.; Zieger, K.; Real, F.X.; Malats, N.; Carrato, A.; Hurst, C.; Kotwal, S.; Knowles, M.; Malmstrom, P.U.; de la Torre, M.; Wester, K.; Allory, Y.; Vordos, D.; Caillault, A.; Radvanyi, F.; Hein, A.M.; Jensen, J.L.; Jensen, K.M.; Marcussen, N.; Orntoft, T.F. Gene expression signatures predict outcome in non-muscleinvasive bladder carcinoma: a multicenter validation study. Clin. Cancer Res., 2007, 13, 3545-3551.
122. Munksgaard, P.P.; Mansilla, F.; Brems Eskildsen, A.-S.; Fristrup, N.; Birkenkamp-Demtröder, K.; Ulhøi, B.P.; Borre, M.; Agerbæk, M.; Hermann, G.G.; Ørntoft, T.F.; Dyrskjøt, L. Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br. J. Cancer, 2011, 105, 1379-1387.
123. Wang, H.; Wang, J.; Zuo, Y.; Ding, M.; Yan, R.; Yang, D.; Ke, C. Expression and prognostic significance of a new tumor metastasis suppressor gene LASS2 in human bladder carcinoma. Med. Oncol., 2011, DOI: 10.1007/s12032-011-0026-6.
124. Zuo, Q.; Wu, W.; Li, X.; Zhao, L.; Chen, W. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol. Rep., 2012, 27, 819-824.
125. Zoidakis, J.; Makridakis, M.; Zerefos, P.G.; Bitsika, V.; Esteban, S.; Frantzi, M.; Stravodimos, K.; Anagnou, N.P.; Roubelakis, M.G.; Sanchez-Carbayo, M.; Vlahou, A. Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol. Cell. Proteomics, 2011, DOI: 10.1074/mcp.M111.009449.
126. Yang, M.-H.; Chu, P.-Y.; Chen, S.C.-J.; Chung, T.-W.; Chen, W.-C.; Tan, L.-B.; Kan, W.-C.; Wang, H.-Y.; Su, S.-B.; Tyan, Y.-C. Characterization of ADAM28 as a biomarker of bladder transitional cell carcinomas by urinary proteome analysis. Biochem. Biophys. Res. Commun., 2011, 411, 714-720.
127. Matsushita, K.; Cha, E.K.; Matsumoto, K.; Baba, S.; Chromecki, T.F.; Fajkovic, H.; Sun, M.; Karakiewicz, P.I.; Scherr, D.S.; Shariat, S.F. Immunohistochemical biomarkers for bladder cancer prognosis. Int. J. Urol., 2011, 18, 616-629.
128. Han, B.; Cui, D.; Jing, Y.; Hong, Y.; Xia, S. Estrogen receptor [(ER() is a novel prognostic marker of recurrence survival in nonmuscle-invasive bladder cancer potentially by inhibiting cadherin switch. World J. Urol., 2012, DOI: 10.1007/s00345-011-0819-4.
129. Miyamoto, H.; Yao, J.L.; Chaux, A.; Zheng, Y.; Hsu, I.; Izumi, K.; Chang, C.; Messing, E.M.; Netto, G.J.; Yeh, S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int., 2012, DOI: 10.1111/j.1464-410X.2011.10706.x.
130. Lindén, M.; Bergström Lind, M.; Mayrhofer, C.; Segersten, U.; Wester, K.; Lyutvinskiy, Y.; Zubarev, R.; Malmström P.-U.; Pettersson U. Proteomic analysis of urinary biomarker candidates for non-muscle invasive bladder cancer. Proteomics, 2012, DOI: 10.1002/pmic.201000810.
131. Pandith, A.A.; Shah, Z.A.; Siddiqi, M.A. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol. Oncol., 2010, DOI: 10.1016/j.urolonc.2010.07.014.
132. Iyer, G.; Milowsky, M.I. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol. Oncol., 2011, DOI: 10.1016/j.urolonc.2011.12.001.
133. Foldynova-Trantirkova, S.; Wilcox, W.R.; Krejci, P. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum. Mutat., 2012, 33, 29-41.
134. Gomez-Roman, J.; Saenz, P.; Conzalez, J.; Escuredo, K.; Santa Cruz, S.; Junquera, C.; Simón, L.; Martínez, A.; Gutiérrez Baños, J.L.; López-Brea, M.; Esparza, C.; Val-Bernal, J.F. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin. Cancer Res., 2005, 11, 459-465.
135. Mhawech-Fauceglia, P.; Fischer, G.; Alvarez, V.; Ahmed, A.; Herrmann, F. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int., 2007, 100, 1182-1187.
136. Knowles, M.A. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J. Urol., 2007, 25, 581-593.
137. Brazil, D.P.; Hemmings, B.A. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem. Sci., 2001, 26, 657-664.
138. Qayyum, T.; Fyffe, G.; Duncan, M.; McArdle, P.A.; Hilmy, M.; Orange, C.; Halbert, G.; Seywright, M.; Horgan, P.G.; Underwood, M.A.; Edwards, J. The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder. Br. J. Cancer, 2012, DOI: 10.1038/bjc.2012.52.
139. Su, W.C.; Kitagawa, M.; Xue, N.; Xie, B.; Garofalo, S.; Cho, J.; Deng, C.; Horton, W.A.; Fu, X.Y. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature, 1997, 386, 288-292.
140. Yang, G.L.; Zhang, L.H.; Bo, J.J.; Huo, X.J.; Chen, H.G.; Cao, M.; Liu, D.M.; Huang, Y.R. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J. Surg. Oncol., 2012, DOI: 10.1002/jso.23040.
141. Izmirli, M.; Inandiklioglu, N.; Abat, D.; Alptekin, D.; Demirhan, O.; Tansug, Z.; Bayazit, Y. MTHFR gene polymorphisms in bladder cancer in the Turkish population. Asian Pac. J. Cancer Prev., 2011, 12, 1833-1835.
142. Wang, Y.H.; Yeh, S.D.; Shen, K.H.; Shen, C.H.; Tung, M.C.; Liu, C.T.; Chiou, H.Y. Association of hOGG1 and XPD polymorphisms with urothelial carcinoma in Taiwan. Anticancer Res., 2011, 31, 3939-3944.
143. Kawashima, A.; Takayama, H.; Tsujimura, A. A review of ERCC1 gene in bladder cancer: implications for carcinogenesis and resistance to chemoradiotherapy. Adv. Urol., 2012, 2012, 812398, DOI: 10.1155/2012/812398.
144. Stern, M.C.; Lin, J.; Figueroa, J.D.; Kelsey, K.T.; Kiltie, A.E.; Yuan, J.M.; Matullo, G.; Fletcher, T.; Benhamou, S.; Taylor, J.A.; Placidi, D.; Zhang, Z.F.; Steineck, G.; Rothman, N.; Kogevinas, M.; Silverman, D.; Malats, N.; Chanock, S.; Wu, X.; Karagas, M.R.; Andrew, A.S.; Nelson, H.H.; Bishop, D.T.; Sak, S.C.; Choudhury, A.; Barrett, J.H.; Elliot, F.; Corral, R.; Joshi, A.D.; Gago-Dominguez, M.; Cortessis, V.K.; Xiang, Y.B.; Gao, Y.T.; Vineis, P.; Sacerdote, C.; Guarrera, S.; Polidoro, S.; Allione, A.; Gurzau, E.; Koppova, K.; Kumar, R.; Rudnai, P.; Porru, S.; Carta, A.; Campagna, M.; Arici, C.; Park, S.S.; Garcia-Closas, M.; International Consortium of Bladder Cancer. Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res., 2009, 69, 6857-6864.
145. Zhu, X.; Zhong, Z.; Zhang, X.; Zhao, X.; Xu, R.; Ren, W.; Li, S. DNA repair gene XRCC3 T241M polymorphism and bladder cancer risk in a chinese population. Genet. Test Mol. Biomarkers., 2012, DOI: 10.1089/gtmb.2011.0334.
146. Teo, M.T.; Landi, D.; Taylor, C.F.; Elliott, F.; Vaslin, L.; Cox, D.G.; Hall, J.; Landi, S.; Bishop, D.T.; Kiltie, A.E. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis, 2012, 33, 581-586.
147. Menashe, I.; Figueroa, J.D.; Garcia-Closas, M.; Chatterjee, N.; Malats, N.; Picornell, A.; Maeder, D.; Yang, Q.; Prokunina-Olsson, L.; Wang, Z.; Real, F.X.; Jacobs, K.B.; Baris, D.; Thun, M.; Albanes, D.; Purdue, M.P.; Kogevinas, M.; Hutchinson, A.; Fu, Y.-P.; Tang, W.; Burdette, L.; Tardón, A.; Serra, C.; Carrato, A.; García-Closas, R.; Lloreta, J.; Johnson, A.; Schwenn, M.; Schned, A.; Andriole Jr, G.; Black, A.; Jacobs, E.J.; Diver, R.W.; Gapstur, S.M.; Weinstein, S.J.; Virtamo, J.; Caporaso, N.E.; Landi, M.T.; Fraumeni Jr, J.F.; Chanock, S.J.; Silverman, D.T.; Rothman, N. Large-scale pathway-based analysis of bladder cancer genomewide association data from five studies of european background. PLoS One, 2012, 7(1), e29396.
148. Tang, W.; Fu, Y.P.; Figueroa, J.D.; Malats, N.; Garcia-Closas, M.; Chatterjee, N.; Kogevinas, M.; Baris, D.; Thun, M.; Hall, J.L.; De Vivo, I.; Albanes, D.; Porter-Gill, P.; Purdue, M.P.; Burdett, L.; Liu, L.; Hutchinson, A.; Myers, T.; Tardón, A.; Serra, C.; Carrato, A.; Garcia-Closas, R.; Lloreta, J.; Johnson, A.; Schwenn, M.; Karagas, M.R.; Schned, A.; Black, A.; Jacobs, E.J.; Diver, W.R.; Gapstur, S.M.; Virtamo, J.; Hunter, D.J.; Fraumeni Jr, J.F.; Chanock, S.J.; Silverman, D.T.; Rothman, N.; Prokunina-Olsson, L. Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Hum. Mol. Genet., 2012, 21, 1918-1930.
149. Safarinejad, M.R.; Safarinejad, S.; Shafiei, N.; Safarinejad, S. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility. Urol. Oncol., 2011, DOI: 10.1016/j.urolonc.2011.11.027.
150. Gong, M.; Dong, W.; An, R. Glutathione S-transferase T1 polymorphism contributes to bladder cancer risk: a meta-analysis involving 50 studies. DNA Cell Biol., 2012, DOI: 10.1089/dna.2011.1567.
151. Salinas-Sánchez, A.S.; Donate-Moreno, M.J.; López-Garrido, M.P.; Giménez-Bachs, J.M.; Escribano, J. Role of CYP1B1 gene polymorphisms in bladder cancer susceptibility. J. Urol., 2012, 187, 700-706.
152. Schiffer, E.; Vlahou, A.; Petrolekas, A.; Stravodimos, K.; Tauber, R.; Geschwend, J. E.; Neuhaus, J.; Stolzenburg, J.-U.; Conaway, M. R.; Mischak, H.; Theodorescu, D. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res., 2009, 15, 4935-4943.
153. Chen, Y.-T.; Chena, H.-W.; Domanskic, D.; Smith, D.S.; Liang, K.-H.; Wu, C.-C.; Chen, C.-L.; Chung, T.; Chen, M.-C.; Chang, Y.-S.; Parker, C.E.; Borchers, C.H.; Yu, J.-S. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J. Proteomics, 2012, DOI: 10.1016/j.jprot.2011.12.031.
154. Holmes, E.; Wilson, I. D.; Nicholson, J. K. Metabolic phenotyping in health and disease. Cell, 2008, 134, 714-717.
155. Spratlin, J.L.; Serkova, N.J.; Eckhardt, S.G. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res., 2009, 15, 431-440.
156. Huang, Z.; Lin, L.; Gao, Y.; Chen, Y.; Yan, X.; Xing, J.; Hang, W. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol. Cell. Proteomics, 2011, DOI: 10.1074/mcp.M111.007922.
157. Lindgren, D.; Liedberg, F.; Andersson, A.; Chebil, G.; Gudjonsson, S.; Borg, A.; Månsson, W.; Fioretos, T.; Höglund, M. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene, 2006, 25, 2685-2696.
158. Simoneau, M.; LaRue, H.; Aboulkassim, T.O.; Meyer, F.; Moore, L.; Fradet, Y. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene, 2000, 19, 6317-6323.
159. Hoffman, A.M.; Cairns, P. Epigenetics of kidney cancer and bladder cancer. Epigenomics, 2011, 3, 19-34.
160. Dudziec, E.; Goepel, J.R.; Catto, J.W. Global epigenetic profiling in bladder cancer. Epigenomics, 2011, 3, 35-45.
161. Christoph, F.; Schmidt, B.; Schmitz-Drager, B.J.; Schulz, W.A. Overexpression and amplification of the c-myc gene in human urothelial carcinoma. Int. J. Cancer, 1999, 84, 169-173.
162. Feber, A.; Clark, J.; Goodwin, G.; Dodson, A.R.; Smith, P.H.; Fletcher, A.; Edwards, S.; Flohr, P.; Falconer, A.; Roe, T.; Kovacs, G.; Dennis, N.; Fisher, C.; Wooster, R.; Huddart, R.; Foster, C.S.; Cooper, C.S. Amplification and overexpression of E2F3 in human bladder cancer. Oncogene, 2004, 23, 1627-1630.
163. Mitra, A.P.; Birkhahn, M.; Cote, R.J. p53 and retinoblastoma pathways in bladder cancer. World J. Urol., 2007, 25, 563-571.
164. Dinney, C.P.; McConkey, D.J.; Millikan, R.E.; Wu, X.; Bar-Eli, M.; Adam, L.; Kamat, A.M.; Siefker-Radtke, A.O.; Tuziak, T.; Sabichi, A.L.; Grossman, H.B.; Benedict, W.F.; Czerniak, B. Focus on bladder cancer. Cancer Cell, 2004, 6, 111-116.
165. Hu, H.; Wang, Y.L.; Wang, G.W.; Wong, Y.C.; Wang, X.F.; Wang, Y.; Xu, K.X. A novel role of Id-1 in regulation of epithelialto-mesenchymal transition in bladder cancer. Urol. Oncol., 2012, DOI: 10.1016/j.urolonc.2011.12.003.
166. Sun, X.F.; Sun, Z.Y.; Pan, B.; Li, L.; Shen, W. Alteration in methylation pattern of oncogene Akt1 promoter region in bladder cancer. Mol. Biol. Rep., 2011, 39, 5631-5636.
167. Shirodkar, S.P.; Lokeshwar, V.B. Potential new urinary markers in the early detection of bladder cancer. Curr. Opin. Urol., 2009, 19, 488-493.
168. Feng, C.C.; Wang, P.H.; Guan, M.; Jiang, H.W.; Wen, H.; Ding, Q.; Wu, Z. Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumor invasiveness. Folia Biol. (Praha), 2011, 57, 242-247.
169. Gecit, I.; Aslan, M.; Gunes, M.; Pirincci, N.; Esen, R.; Demir, H.; Ceylan, K. Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer. J. Cancer Res. Clin. Oncol., 2012, DOI 10.1007/s00432-011-1136-4.
170. Chatterjee, S.J.; Datar, R.; Youssefzadeh, D.; George, B.; Goebell, P.J.; Stein, J.P.; Young, L.; Shi, S.R.; Gee, C.; Groshen, S.; Skinner, D.G.; Cote, R.J. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol., 2004, 22, 1007-1013.
171. Chapman, E.J.; Harnden, P.; Chambers, P.; Johnston, C.; Knowles, M.A. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin. Cancer Res., 2005, 11, 5740-5747.
172. Marín-Aguilera, M.; Mengual, L.; Ribal, M.J.; Ars, E.; Ríos, J.; Gázquez, C.; Villavicencio, H.; Alcaraz, A. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology, 2012, 79, 240. e9-240. e15.
173. Riester, M.; Taylor, J.; Feifer, A.; Koppie, T.M.; Rosenberg, J.; Downey, R.J.; Bochner, B.H.; Michor, F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin. Cancer Res., 2012, 18, 1323-1333.
174. Stransky, N.; Vallot, C.; Reyal, F.; Bernard-Pierrot, I.; de Medina, S.G.; Segraves, R.; de Rycke, Y.; Elvin, P.; Cassidy, A.; Spraggon, C.; Graham, A.; Southgate, J.; Asselain, B.; Allory, Y.; Abbou, C.C.; Albertson, D.G.; Thiery, J.P.; Chopin, D.K.; Pinkel, D.; Radvanyi, F. Regional copy number-independent deregulation of transcription in cancer. Nat. Genet., 2006, 38, 1386-1396.
175. Vallot, C.; Stransky, N.; Bernard-Pierrot, I.; Hérault, A.; Zucman-Rossi, J.; Chapeaublanc, E.; Vordos, D.; Laplanche, A.; Benhamou, S.; Lebret, T.; Southgate, J.; Allory, Y.; Radvanyi, F. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J. Natl. Cancer Inst., 2011, 103, 47-60.
176. Sánchez-Carbayo, M. Hypermethylation in bladder cancer: biological pathways and translational applications. Tumor Biol., 2012, 33, 347-361.
177. Tada; Y.; Wada, M.; Taguchi, K.; Mochida, Y.; Kinugawa, N.; Tsuneyoshi, M.; Naito, S.; Kuwano, M. The association of deathassociated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res., 2002, 62, 4048-4053.
178. Catto, J.W.; Azzouzi, A.R.; Rehman, I.; Feeley, K.M.; Cross, S.S.; Amira, N.; Fromont, G.; Sibony, M.; Cussenot, O.; Meuth, M.; Hamdy, F.C. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol., 2005, 23, 2903-2910.
179. Hellwinkel, O.J.C.; Kedia, M.; Isbarn, H.; Budäus, L.; Friedrich, M.G. Methylation of the TPEF-and PAX6-promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumors. BJU Int., 2007, 101, 753-757.
180. Yates, D.R.; Rehman, I.; Abbod, M.F.; Meuth, M.; Cross, S.S.; Linkens, D.A.; Hamdy, F.C.; Catto, J.W. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res., 2007, 13, 2046-2053.
181. Jarmalaite, S.; Jankevicius, F.; Kurgonaite, K.; Suziedelis, K.; Mutanen, P.; Husgafvel-Pursiainen, K. Promoter hypermethylation in tumor suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology, 2008, 75, 145-151.
182. Eissa, S.; Zohny, S.F.; Shehata, H.H.; Hegazy, M.G.A.; Salem, A.M.; Esmat, M. Urinary retinoic acid receptor->>2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer. Clin. Biochem., 2012, 45, 402-407.
183. Kandimalla, R.; van Tilborg, A.A.G.; Kompier, L.C.; Stumpel, D.J.P.M.; Stam, R.W.; Bangma, C.H.; Zwarthoff, E.C. Genomewide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur. Urol., 2012, DOI: 10.1016/j.eururo.2012.01.011.
184. Bornman, D.M.; Mathew, S.; Alsruhe, J.; Herman, J.G.; Gabrielson, E. Methylation of the E-cadherin gene in bladder neoplasia and in normal urothelial epithelium from elderly individuals. Am. J. Pathol., 2001, 159, 831-835.
185. Marsit, C.J.; Houseman, E.A.; Schned, A.R.; Karagas, M.R.; Kelsey, K.T. Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis, 2007, 28, 1745-1751.
186. Yang, W.; Cui, S.; Ma, J.; Lu, Q.; Kong, C.; Liu, T.; Sun, Z. Cigarette smoking extract causes hypermethylation and inactivation of WWOX gene in T-24 human bladder cancer cells. Neoplasma, 2012, 59, 216-223.
187. Lin, H.H.; Ke, H.L.; Huang, S.P.; Wu, W.J.; Chen, Y.K.; Chang, L.L. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol. Oncol., 2010, 28, 597-602.
188. Jablonowski, Z.; Reszka, E.; Gromadzinska, J.; Wasowicz, W.; Sosnowski, M. Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. Arch. Med. Sci., 2011, 7, 512-516.
189. Lin, H.H.; Ke, H.L.; Wu, W.J.; Lee, Y.H.; Chang, L.L. Hypermethylation of E-cadherin, p16, p14, and RASSF1A genes in pathologically normal urothelium predict bladder recurrence of bladder cancer after transurethral resection. Urol. Oncol., 2012, 30, 177-181.
190. Lee, M.G.; Kim, H.Y.; Byun, D.S. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res., 2001, 61, 6688-6692.
191. Chen, P.C.; Tsai, M.H.; Yip, S.K.; Jou, Y.C.; Ng, C.F.; Chen, Y.; Wang, X.; Huang, W.; Tung, C.L.; Chen, G.C.; Huang, M.M.; Tong, J.H.; Song, E.J.; Chang, D.C.; Hsu, C.D.; To, K.F.; Shen, C.H.; Chan, M.W. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med. Genomics, 2011, 4, 45.
192. Tolg, C.; Sabha, N.; Cortese, R.; Panchal, T.; Ahsan, A.; Soliman, A.; Aitken, K.J.; Petronis, A.; Bägli, D.J. Uropathogenic E. coli infection provokes epigenetic downregulation of CDKN2A (p16INK4A) in uroepithelial cells. Lab. Invest., 2011, 91, 825-836.
193. Kim, E.J.; Kim, Y.J.; Jeong, P.; Ha, Y.S.; Bae, S.C.; Kim, W.J. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J. Urol., 2008, 180, 1141-1145.
194. Aleman, A.; Adrien, L.; Lopez-Serra, L.; Cordon-Cardo, C.; Esteller, M.; Belbin, T.J.; Sanchez-Carbayo, M. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br. J. Cancer, 2008, 98, 466-473.
195. Ha, Y.S.; Kim, J.S.; Yoon, H.Y.; Jeong, P.; Kim, T.H.; Yun, S.J.; Lee, S.C.; Kim, G.Y.; Choi, Y.H.; Moon, S.K.; Yi Kim, I.; Kim, W.J. Novel combination markers for predicting progression of nonmuscle invasive bladder cancer. Int. J. Cancer, 2011, DOI: 10.1002/ijc.27319.
196. Yan, C.; Kim, Y.W.; Ha, Y.S.; Kim, I.Y.; Kim, Y.J.; Yun, S.J.; Moon, S.K.; Bae, S.C.; Kim, W.J. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer. J. Surg. Oncol., 2012, 105, 425-430.
197. Urakami, S.; Shiina, H.; Enokida, H.; Kawakami, T.; Tokizane, T.; Ogishima, T.; Tanaka, Y.; Li, L.C.; Ribeiro-Filho, L.A.; Terashima, M.; Kikuno, N.; Adachi, H.; Yoneda, T.; Kishi, H.; Shigeno, K.; Konety, B.R.; Igawa, M.; Dahiya, R. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/ß-Catenin signaling pathway. Clin. Cancer Res., 2006, 12, 383-391.
198. Urakami, S.; Shiina, H.; Enokida, H.; Kawakami, T.; Kawamoto, K.; Hirata, H.; Tanaka, Y.; Kikuno, N.; Nakagawa, M.; Igawa, M.; Dahiya, R. Combination analysis of hypermethylated Wntantagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin. Cancer Res., 2006, 12, 2109-2116.
199. Stoehr, R.; Wissmann, C.; Suzuki, H.; Knuechel, R.; Krieg, R.C.; Klopocki, E.; Dahl, E.; Wild, P.; Blaszyk, H.; Sauter, G.; Simon, R.; Schmitt, R.; Zaak, D.; Hofstaedter, F.; Rosenthal, A.; Baylin, S.B.; Pilarsky, C.; Hartmann, A. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab. Invest., 2004, 84, 465-478.
200. Marsit, C.J.; Karagas, M.R.; Andrew, A.; Liu, M.; Danaee, H.; Schned, A.R.; Nelson, H.H.; Kelsey, K.T. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res., 2005, 65, 7081-7085.
201. Khin, S.S.; Kitazawa, R.; Win, N.; Aye, T.T.; Mori, K.; Kondo, T.; Kitazawa, S. BAMBI gene is epigenetically silenced in subset of high-grade bladder cancer. Int. J. Cancer, 2009, 125, 328-338.
202. Du, P.; Ye, L.; Li, H.; Ruge, F.; Yang, Y.; Jiang, W.G. Growth differentiation factor-9 expression is inversely correlated with an aggressive behaviour in human bladder cancer cells. Int. J. Mol. Med., 2012, 29, 428-434.
203. Hinz, S.; Kempkensteffen, C.; Weikert, S.; Schostak, M.; Schrader, M.; Miller, K.; Christoph, F. EZH2 polycomb transcriptional repressor expression correlates with methylation of the APAF-1 gene in superficial transitional cell carcinoma of the bladder. Tumor Biol., 2007, 28, 151-157.
204. Zuiverloon, T.C.M.; Beukers, W.; van der Keur, K.A.; Munoz, J.R.; Bangma, C.H.; Lingsma, H.F.; Eijkemans, M.J.C.; Schouten, J.P.; Zwarthoff, E.C. A methylation assay for the detection of nonmuscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int., 2012, 109, 941-948.
205. Li, W.; Xia, D.; Wang, Y.; Li, Y.; Xue, Y.; Wu, X.; Ye, Z. Relationship between aberrant methylation of FAS promoter and biological behavior of bladder urothelial carcinoma. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2011, 31, 794-798.
206. Costa, V.L.; Henrique, R.; Danielsen, S.A.; Duarte-Pereira, S.; Eknaes, M.; Skotheim, R.I.; Rodrigues, A.; Magalhães, J.S.; Oliveira, J.; Lothe, R.A.; Teixeira, M.R.; Jerónimo, C.; Lind, G.E. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res., 2010, 16, 5842-5851.
207. Reinert, T.; Modin, C.; Castano, F.M.; Lamy, P.; Wojdacz, T.K.; Hansen, L.L.; Wiuf, C.; Borre, M.; Dyrskjøt, L.; Ørntoft, T.F. Comprehensive genome methylation analysis in bladder cancer; identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin. Cancer Res., 2011, 17, 5582-5592.
208. Dyrskjøt, L.; Thykjaer, T.; Kruhøffer, M.; Jensen, J.L.; Marcussen, N.; Hamilton-Dutoit, S.; Wolf, H.; Orntoft, T.F. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet., 2003, 33, 90-96.
209. Satge, D.; Sasco, A.J.; Day, S.; Culine, S. A lower risk of dying from urological cancer in Down syndrome: clue for cancer protecting genes on chromosome 21. Urol. Int., 2009, 82, 296-300.
210. Malinge, S.; Izraeli, S.; Crispino, J.D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood, 2009, 113, 2619-2628.
211. Cebrian, V.; Alvarez, M.; Aleman, A.; Palou, J.; Bellmunt, J.; Gonzalez-Peramato, P.; Cordón-Cardo, C.; García, J.; Piulats, J.M.; Sánchez-Carbayo, M. Discovery of myopodin methylation in bladder cancer. J. Pathol., 2008, 216, 111-119.
212. Aleman, A.; Cebrian, V.; Alvarez, M.; Lopez, V.; Orenes, E.; Lopez-Serra, L.; Algaba, F.; Bellmunt, J.; López-Beltrán, A.; Gonzalez-Peramato, P.; Cordón-Cardo, C.; García, J.; del Muro, J.G.; Esteller, M.; Sánchez-Carbayo, M. Identification of PMF1 methylation in association with bladder cancer progression. Clin. Cancer Res., 2008, 14, 8236-8243.
213. Hoque, M.O.; Begum, S.; Brait, M.; Jeronimo, C.; Zahurak, M.; Ostrow, K.L.; Rosenbaum, E.; Trock, B.; Westra, W.H.; Schoenberg, M.; Goodman, S.N.; Sidransky, D. Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. J. Urol., 2008, 179, 743-747.
214. Renard, I.; Joniau, S.; van Cleynenbreugel, B.; Collette, C.; Naome, C.; Vlassenbroeck, I.; Nicolas, H.; de Leval, J.; Straub, J.; Van Criekinge, W.; Hamida, W.; Hellel, M.; Thomas, A.; de Leval, L.; Bierau, K.; Waltregny, D. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur Urol., 2010, 58, 96-104.
215. Friedrich, M.G.; Weisenberger, D.J.; Cheng, J.C.; Chandrasoma, S.; Siegmund, K.D.; Gonzalgo, M.L.; Toma, M.I.; Huland, H.; Yoo, C.; Tsai, Y.C.; Nichols, P.W.; Bochner, B.H.; Jones, P.A.; Liang, G. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res., 2004, 10, 7457-7465.
216. Sobti, R.C.; MalekZadeh, K.; Nikbakht, M.; Sadeghi, I.A.; Shekari, M.; Singh, S.K. Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer. Biomarkers, 2010, 15, 167-174.
217. Serizawa, R.R.; Ralfkiaer, U.; Steven, K.; Lam, G.W.; Schmiedel, S.; Schüz, J.; Hansen, A.B.; Horn, T.; Guldberg, P. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int. J. Cancer, 2011, 129, 78-87.
218. Lokeshwar, V.B.; Gomez, P.; Kramer, M.; Knapp, J.; McCornack, M.A.; Lopez, L.E.; Fregien, N.; Dhir, N.; Scherer, S.; Klumpp, D.J.; Manoharan, M.; Soloway, M.S.; Lokeshwar, B.L. Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J. Biol. Chem., 2008, 283, 29215-29227.
219. Mori, K.; Enokida, H.; Kagara, I.; Kawakami, K.; Chiyomaru, T.; Tatarano, S.; Kawahara, K.; Nishiyama, K.; Seki, N.; Nakagawa, M. CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer. Int. J. Oncol., 2009, 34, 1593-1602.
220. Wang, X.S.; Zhang, Z.; Wang, H.C.; Cai, J.L.; Xu, Q.W.; Li, M.Q.; Chen, Y.C.; Qian, X.P.; Lu, T.J.; Yu, L.Z.; Zhang, Y.; Xin, D.Q.; Na, Y.Q.; Chen, W.F. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin. Cancer Res., 2006, 12, 4851-4858.
221. Wang, F.; Lia, X.; Xie, X.J.; Zhao, L.; Chen, W. UCA1, a nonprotein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett., 2008, 582, 1919-1927.
222. Yang, C.; Li, X.; Wang, Y.; Zhao, L.; Chen, W. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene, 2012, 496, 8-16.
223. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet., 2009, 10, 704-714.
224. Choudhry, H.; Catto, J.W. Epigenetic regulation of microRNA expression in cancer. Methods Mol. Biol., 2010, 676, 165-184.
225. Dudziec, E.; Miah, S.; Choudhury, H.M.Z.; Owen, H.C.; Blizard, S.; Glover, M.; Hamdy, F.C.; Catto, J.W. Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin. Cancer Res., 2011, 17, 1287-1296.
226. Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136, 215-233.
227. Guo, H.; Ingolia, N.T.; Weissman, J.S.; Bartel, D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature, 2010, 466, 835-840.
228. Catto, J.W.F.; Alcaraz, A.; Bjartell, A.S.; De Vere White, R.; Evans, C.P.; Fussel, S.; Hamdy, F.C.; Kallioniemi, O.; Mengual, L.; Schlomm, T.; Visakorpi, T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol., 2011, 59, 671-681.
229. Wu, D.; Tao, J.; Xu, B.; Li, P.; Lu, Q.; Zhang, W. Downregulation of Dicer, a component of the microRNA machinery, in bladder cancer. Mol. Med. Report., 2012, 5, 695-699.
230. Wiklund, E.D.; Bramsen, J.B.; Hulf, T.; Dyrskjøt, L.; Ramanathan, R.; Hansen, T.B.; Villadsen, S.B.; Gao, S.; Ostenfeld, M.S.; Borre, M.; Peter, M.E.; Ørntoft, T.F.; Kjems, J.; Clark, S.J. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer, 2011, 128, 1327-1334.
231. Zhu, J.; Jiang, Z.; Gao, F.; Hu, X.; Zhou, L.; Chen, J.; Luo, H.; Sun, J.; Wu, S.; Han, Y.; Yin, G.; Chen, M.; Han, Z.; Li, X.; Huang, Y.; Zhang, W.; Zhou, F.; Chen, T.; Fa, P.; Wang, Y.; Sun, L.; Leng, H.; Sun, F.; Liu, Y.; Ye, M.; Yang, H.; Cai, Z.; Gui, Y.; Zhang, X. A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer. PLoS One, 2011, 6(11), e28223.
232. Han, Y.; Chen, J.; Zhao, X.; Liang, C.; Wang, Y.; Sun, L.; Jiang, Z.; Zhang, Z.; Yang, R.; Chen, J.; Li, Z.; Tang, A.; Li, X.; Ye, J.; Guan, Z.; Gui, Y.; Cai, Z. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One, 2011, 6(3), e18286.
233. Li, X.; Chen, J.; Hu, X.; Huang, Y.; Li, Z.; Zhou, L.; Tian, Z.; Ma, H.; Wu, Z.; Chen, M.; Han, Z.; Peng, Z.; Zhao, X.; Liang, C.; Wang, Y.; Sun, L.; Chen, J.; Zhao, J.; Jiang, B.; Yang, H.; Gui, Y.; Cai, Z.; Zhang, X. Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events. PLoS One, 2011, 6(7), e22570.
234. Catto, J.W.F.; Miah, S.; Owen, H.C.; Bryant, H.; Myers, K.; Dudziec, E.; Larré, S.; Milo, M.; Rehman, I.; Rosario, D.J.; Di Martino, E.; Knowles, M.A.; Meuth, M.; Harris, A.L.; Hamdy, F.C. Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res., 2009, 69, 8472-8481.
235. Veerla, S.; Lindgren, D.; Kvist, A.; Frigyesi, A.; Staaf, J.; Persson, H.; Liedberg, F.; Chebil, G.; Gudjonsson, S.; Borg, A.; Månsson, W.; Rovira, C.; Höglund, M. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer, 2009, 124, 2236-2242.
236. Dalmay, T.; Edwards, D.R. MicroRNAs and the hallmarks of cancer. Oncogene, 2006, 25, 6170-6175.
237. Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 2007, 133, 647-658.
238. Tao, J.; Lu, Q.; Wu, D.; Li, P.; Xu, B.; Qing, W.; Wang, M.; Zhang, Z.; Zhang, W. microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol. Rep., 2011, 25, 1721-1729.
239. Zhu, S.; Si, M.L.; Wu, H.; Mo, Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem., 2007, 282, 14328-14336.
240. Catto, J.W.; Xinarianos, G.; Burton, J.L.; Meuth, M.; Hamdy, F.C. Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. Int. J. Cancer, 2003, 105, 484-490.
241. Oeggerli, M.; Tomovska, S.; Schraml, P.; Calvano-Forte, D.; Schafroth, S.; Simon, R.; Gasser, T.; Mihatsch, M.J.; Sauter, G. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene, 2004, 23, 5616-5623.
242. Huang, L.; Luo, J.; Cai, Q.; Pan, Q.; Zeng, H.; Guo, Z.; Dong, W.; Huang, J.; Lin, T. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int. J. Cancer, 2011, 128, 1758-1769.
243. Miles, W.O.; Tschöp, K.; Herr, A.; Ji, J.-Y.; Dyson, N.J. Pumilio facilitates miRNA regulation of the E2F3 oncogene. Genes Dev., 2012, 26, 356-368.
244. Yoshino, H.; Enokida, H.; Chiyomaru, T.; Tatarano, S.; Hidaka, H.; Yamasaki, T.; Gotannda, T.; Tachiwada, T.; Nohata, N.; Yamane, T.; Seki, N.; Nakagawa, M. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem. Biophys. Res. Commun., 2012, 417, 588-593.
245. Neely, L.A.; Rieger-Christ, K.M.; Silva Neto, B.; Eroshkin, A.; Garver, J.; Patel, S.; Phung, N.A.; McLaughlin, S.; Libertino, J.A.; Whitney, D.; Summerhayes, I.C. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol. Oncol., 2010, 28, 39-48.
246. Lin, Y.; Wu, J.; Chen, H.; Mao, Y.; Liu, Y.; Mao, Q.; Yang, K.; Zheng, X.; Xie, L. Cyclin-dependent kinase 4 is a novel target in microRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett., 2012, 586, 442-447.
247. Adam, L.; Zhong, M.; Choi, W.; Qi, W.; Nicoloso, M.; Arora, A.; Calin, G.; Wang, H.; Siefker-Radtke, A.; McConkey, D.; Bar-Eli, M.; Dinney, C. miR-200 expression regulates epithelial-tomesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res., 2009, 15, 5060-5072.
248. Kenney, P.A.; Wszolek, M.F.; Rieger-Christ, K.M.; Neto, B.S.; Gould, J.J.; Harty, N.J.; Mosquera, J.M.; Zeheb, R.; Loda, M.; Darling, D.S.; Libertino, J.A.; Summerhayes, I.C. Novel ZEB1 expression in bladder tumorigenesis. BJU Int., 2011, 107, 656-563.
249. Burk, U.; Schubert, J.; Wellner, U.; Schmalhofer, O.; Vincan, E.; Spaderna, S.; Brabletz, T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep., 2008, 9, 582-589.
250. Shen, A.; Zhang, Y.; Yang, H.; Xu, R.; Huang, G. Overexpression of ZEB1 relates to metastasis and invasion in osteosarcoma. J. Surg. Oncol., 2011, DOI: 10.1002/jso.23012.
251. Chen, H.; Lin, Y.-W.; Mao, Y.-Q.; Wu, J.; Liu, Y.-F.; Zheng, X.-Y.; Xie, L.-P. MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. Cancer Lett., 2012, 320, 40-47.
252. Ueno, K.; Hirata, H.; Majid, S.; Yamamura, S.; Shahryari, V.; Tabatabai, Z.L.; Hinoda, Y.; Dahiya, R. Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by down-regulating RhoC and FZD4. Mol. Cancer Ther., 2012, 11, 244-253.
253. Hirata, H.; Hinoda, Y.; Ueno, K.; Shahryari, V.; Tabatabai, Z.L.; Dahiya, R. MicroRNA-1826 tar gets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis, 2012, 33, 41-48.
254. Lin, T.X.; Dong, W.; Huang, J.; Pan, Q.; Fan, X.; Zhang, C.; Huang, L. MicroRNA-143 as a tumor suppressor for bladder cancer. J. Urol., 2009, 181, 1372-1380.
255. Noguchi, S.; Mori, T.; Hoshino, Y.; Maruo, K.; Yamada, N.; Kitade, Y.; Naoe, T.; Akao, Y. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett., 2011, 307, 211-220.
256. Villadsen, S.B.; Bramsen, J.B.; Ostenfeld, M.S.; Wiklund, E.D.; Fristrup, N.; Gao, S.; Hansen, T.B.; Jensen, T.I.; Borre, M.; Ørntoft, T.F.; Dyrskjøt, L.; Kjems, J. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br. J. Cancer, 2012, 106, 366-374.
257. Gottardo, F.; Liu, C.G.; Ferracin, M.; Calin, G.A.; Fassan, M.; Bassi, P.; Sevignani, C.; Byrne, D.; Negrini, M.; Pagano, F.; Gomella, L.G.; Croce, C.M.; Baffa, R. Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol., 2007, 25, 387-392.
258. Garofalo, M.; Di Leva, G.; Romano, G.; Nuovo, G.; Suh, S.S.; Ngankeu, A.; Taccioli, C.; Pichiorri, F.; Alder, H.; Secchiero, P.; Gasparini, P.; Gonelli, A.; Costinean, S.; Acunzo, M.; Condorelli, G.; Croce, C.M. miR-221 and 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16, 498-509.
259. Dyrskjøt, L.; Ostenfeld, M.S.; Bramsen, J.B.; Silahtaroglu, A.N.; Lamy, P.; Ramanathan, R.; Fristrup, N.; Jensen, J.L.; Andersen, C.L.; Zieger, K.; Kauppinen, S.; Ulhøi, B.P.; Kjems, J.; Borre, M.; Orntoft, T.F. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res., 2009, 69, 4851-4860.
260. Boominathan, L. The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One, 2010, 5(5), e10615.
261. Tao, J.; Wu, D.; Li, P.; Xu, B.; Lu, Q.; Zhang, W. microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Mol. Med. Report, 2012, 5, 167-172.
262. Ichimi, T.; Enokida, H.; Okuno, Y.; Kunimoto, R.; Chiyomaru, T.; Kawamoto, K.; Kawahara, K.; Toki, K.; Kawakami, K.; Nishiyama, K.; Tsujimoto, G.; Nakagawa, M.; Seki, N. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer, 2009, 125, 345-352.
263. Baffa, R.; Fassan, M.; Volinia, S.; O'Hara, B.; Liu, C.G.; Palazzo, J.P.; Gardiman, M.; Rugge, M.; Gomella, L.G.; Croce, C.M.; Rosenberg, A. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol., 2009, 219, 214-221.
264. Hanke, M.; Hoefig, K.; Merz, H.; Feller, A.C.; Kausch, I.; Jocham, D.; Warnecke, J.M.; Sczakiel, G. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol., 2010, 28, 655-661.
265. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem., 2010, 56, 1733-1741.
266. Catto, J.W.F.; Abbod, M.F.; Wild, P.J.; Linkens, D.A.; Pilarsky, C.; Rehman, I.; Rosario, D.J.; Denzinger, S.; Burger, M.; Stoehr, R.; Knuechel, R.; Hartmann, A.; Hamdy, F.C. The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur. Urol., 2010, 57, 398-406.
267. Wang, G.; Zhang, H.; He, H.; Tong, W.; Wang, B.; Liao, G.; Chen, Z.; Du, C. Up-regulation of microRNA in bladder tumor tissue is not common. Int. Urol. Nephrol, 2010, 42, 95-102.
268. Chen, Y.-H.; Wang, S.-Q.; Wu, X.-L.; Shen, M.; Chen, Z.-G.; Chen, X.-G.; Liu, Y.-X.; Zhu, X.-L.; Guo, F.; Duan, X.-Z.; Han, X.-C.; Tao, Z.-H. Characterization of microRNAs expression profiling in one group of Chinese urothelial cell carcinoma identified by Solexa sequencing. Urol. Oncol., 2011, DOI: 10.1016/j.urolonc.2010.11.007.